MSB 7.69% $1.19 mesoblast limited

Ann: FDA Advisory Committee Sets Review Date for Remestemcel-L, page-299

  1. 380 Posts.
    lightbulb Created with Sketch. 312
    Dear god PLEASE Posters if you don’t have a relevant university degree in science, experience in this field, or have personal anecdotal experience with the diseases or product DO NOT make submissions to the ODAC.
    The professionals speaking at the AdCom will handle the negative submissions. If you really think they won’t know any information that we have access to, you’re deluded. They will know everything we know and more.

    If you dont meet any of the above and submit comments, you run the risk of undermining people who deserve to have their story heard, like Meredith from Yankee’s post.
    Last edited by JonesingPanda: 08/08/20
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.